Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Treatment of Warthin's tumor: sclerotherapy and its natural course
2024-518794-33-00Phase 4Authorised
- Sponsor
- Helsinki University Hospital
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of bleomycin in Warthin tumor (WT) (2 arms), sponsored by Helsinki University Hospital. Primary endpoints: Volume change and symptom change at 6 months and Volume change and symptom change at 12 months. Planned start Nov 2024; status: authorised.
02
Drugs
bleomycin
03
Conditions
Warthin tumor (WT)
Beyond the preview
Go deeper on 2024-518794-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-518794-33-00.